337 related articles for article (PubMed ID: 37025994)
1. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Del Baldo G; Del Bufalo F; Pinacchio C; Carai A; Quintarelli C; De Angelis B; Merli P; Cacchione A; Locatelli F; Mastronuzzi A
Front Immunol; 2023; 14():1142597. PubMed ID: 37025994
[TBL] [Abstract][Full Text] [Related]
2. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
4. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
5. CAR-T cells for pediatric brain tumors: Present and future.
Leruste A; Beccaria K; Doz F
Bull Cancer; 2021 Oct; 108(10S):S109-S116. PubMed ID: 34920793
[TBL] [Abstract][Full Text] [Related]
6. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
7. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
8. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B
Front Immunol; 2021; 12():634031. PubMed ID: 34163465
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
10. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
11. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
12. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety.
Vitanza NA; Ronsley R; Choe M; Henson C; Breedt M; Barrios-Anderson A; Wein A; Brown C; Beebe A; Kong A; Kirkey D; Lee BM; Leary SES; Crotty EE; Hoeppner C; Holtzclaw S; Wilson AL; Gustafson JA; Foster JB; Iliff JJ; Goldstein HE; Browd SR; Lee A; Ojemann JG; Pinto N; Gust J; Gardner RA; Jensen MC; Hauptman JS; Park JR
Neoplasia; 2023 Feb; 36():100870. PubMed ID: 36599192
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
14. Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
Huang J; Li YB; Charlebois C; Nguyen T; Liu Z; Bloemberg D; Zafer A; Baumann E; Sodja C; Leclerc S; Fewell G; Liu Q; Prabhakarpandian B; McComb S; Stanimirovic DB; Jezierski A
Fluids Barriers CNS; 2022 Jun; 19(1):38. PubMed ID: 35650594
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401
[TBL] [Abstract][Full Text] [Related]
16. CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies.
Antonucci L; Canciani G; Mastronuzzi A; Carai A; Del Baldo G; Del Bufalo F
Front Immunol; 2022; 13():867154. PubMed ID: 35603195
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
18. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
19. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
